| Literature DB >> 11354539 |
Abstract
The role of cytoreductive surgery in patients with metastatic renal cancer remains controversial. Recent data from our Southwest Oncology Group trial suggest that cytoreduction confers an approximately 50% increase in median survival for such patients when they are treated with interferon-alfa-2b immunotherapy. The timing of cytoreduction, and in which patients it may be most applicable, are discussed herein.Entities:
Mesh：
Year: 2001 PMID： 11354539
Source DB: PubMed Journal: Semin Urol Oncol ISSN： 1081-0943